[
    [
        {
            "time": "",
            "original_text": "科伦药业创仿结合发力自主研发药物制剂业务销售或超百亿",
            "features": {
                "keywords": [
                    "科伦药业",
                    "创仿结合",
                    "自主研发",
                    "药物制剂",
                    "销售"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "科伦药业创仿结合发力自主研发药物制剂业务销售或超百亿",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "第二批“4+7”带量采购如箭在弦，我们做了这6点猜想",
            "features": {
                "keywords": [
                    "4+7",
                    "带量采购",
                    "政策",
                    "猜想"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "第二批“4+7”带量采购如箭在弦，我们做了这6点猜想",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 4,
                "Market_Scope": 10,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "恒瑞470名！20家药企入围2019年中国500强排行榜！",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "中国500强",
                    "排名"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞470名！20家药企入围2019年中国500强排行榜！",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[\"科\"公司峰会]恒瑞医药研发人少费用多药明康德反之",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "研发",
                    "费用",
                    "药明康德"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[\"科\"公司峰会]恒瑞医药研发人少费用多药明康德反之",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "北上资金今日买入招商银行超3亿元",
            "features": {
                "keywords": [
                    "北上资金",
                    "招商银行",
                    "买入"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北上资金今日买入招商银行超3亿元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "医疗保健：坚持投资主线 荐11股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "投资主线",
                    "荐股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗保健"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医疗保健：坚持投资主线 荐11股",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "科创板大幕正徐徐拉开，成长板块估值或提升 关注两大投资方向",
            "features": {
                "keywords": [
                    "科创板",
                    "成长板块",
                    "估值",
                    "投资方向"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "科创板大幕正徐徐拉开，成长板块估值或提升 关注两大投资方向",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药板块小幅走高 天目药业兴齐眼药等涨停",
            "features": {
                "keywords": [
                    "医药板块",
                    "走高",
                    "天目药业",
                    "兴齐眼药",
                    "涨停"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药板块小幅走高 天目药业兴齐眼药等涨停",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "西南证券：科创板的大幕会如何拉开",
            "features": {
                "keywords": [
                    "西南证券",
                    "科创板",
                    "大幕"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "西南证券：科创板的大幕会如何拉开",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "2019年上半年91个药品入选 新药申请超50%",
            "features": {
                "keywords": [
                    "2019年",
                    "药品",
                    "新药申请",
                    "入选"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "2019年上半年91个药品入选 新药申请超50%",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "当心“伪白马股”爆雷",
            "features": {
                "keywords": [
                    "伪白马股",
                    "爆雷"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全行业"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "当心“伪白马股”爆雷",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药:抗肿瘤重磅首仿获批,持续完善肿瘤产品",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "抗肿瘤",
                    "首仿",
                    "获批",
                    "肿瘤产品"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞医药:抗肿瘤重磅首仿获批,持续完善肿瘤产品",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]